Abstract: -Carboline and its naturally obtained analogs are of importance due to their wide range of biological properties. In the present review, we intend to discuss the main trends in the synthesis of -carboline analogs based on pyridine derivatives (including the Fischer synthesis, Graebe-Ullmann reaction, photochemical cyclization, arylation of substituted pyridines, quinolines, etc.) and indole derivatives in order to compare the potential of finding novel drugs in this series. In other words the development, current status and innovative new options for the design and synthesis of -carboline analogs are reviewed here. Published data about the various pharmacological functions and the spectroscopy of compounds belonging to this series are summarized. It also discusses the scope, future perspectives and the problems yet to be explored with respect to the synthesis of functionalised bioactive heteroannulated -carbolines in search of novel drugs.
INTRODUCTION
-Carbolines are the least studied class of compounds compared to their , , and -analogs, although their methods of synthesis, chemical and biochemical characteristics are of undoubted interest. For this reason, we considered it expedient to devote this review to 5H-pyrido [3,2-b] indoles ( -carbolines) with the numbering employed as in 1 (Fig. (1) ). Effective drugs have not yet been found among -carbolines. Nevertheless, a rather broad spectrum of biological activity ( Table 1 ) has been reported for several compounds of this class. A large group of -carboline analogs have exhibited antimuscarinic [1] , antihyperglycemic [2] , antimalarial [3] , antiplasmodial [4] , antifungal [5] , anticryptococcal [6] antiviral [7] and antitumor [8] activity. Recently, cryptolepine and its analogs 2-9 ( Fig. (1) ) have been reported for their cytotoxicity against B16 melanoma and M109 Madison lung cancer cells. They have also been reported to interact with Topoisomerase II inhibiting DNA synthesis [9, 10] . Activates different molecular pathways to inhibit cell cycle progression in a dose dependent manner in human lung adenocarcinoma A549 cells [87] .
Inhibits nuclear factor (NF)-B at 2.5-10 μM in human HEK 293 cells indicating anti-inflammatory action by blocking DNA binding of activated NF-B and thus transcription of NF-B regulated proinflammatory proteins.
Stabilizes topoisomerase II-DNA covalent complexes. It is a potent topoisomerase II inhibitor and also inhibits DNA synthesis [9] .
Apoptosis via Caspase -3-activation Genotoxicity
Antimuscarinic [1] , Antihyperglycemic [2] Antiphospholipase A2 activity, Antiaggrigatory [95, 96] , Vasodilation in isolated perfused kidney of rat. Antiplatelet [97] , antithrombotic [96] and fibrinolytic [98] I N N H 3 C Cryptolepine Anticryptococcal activity [6] Antiinfective [51] , Antifungal [5, 56] , Antibacterial [56] , Antiplasmodial [4, 45] , Antitrypanosomal [45] , Antimalerial activity [3] Kestelevn et al., have patented a series of substitutedcarboline derivatives with the general formula shown in (Fig. (2) ) as HIV inhibitors either in combination with the existing HIV inhibitors or separate or for the sequential use in treatment of retroviral infections such as HIV infection or multi drug resistant retroviruses [11] . 
CHEMISTRY OF -CARBOLINES

Synthetic Methods
Fischer Reaction
The Fischer reaction has proved to be the most common and versatile method for preparing tetrahydrocarboline ring systems. There are two approaches to Fischer reaction for the synthesis of carbolines. The first approach is the formation and cyclization of arylhydrazones of N-alkylpiperid-4-ones in the presence of acid catalysts. The second approach is the thermal cyclization of pyridyl-3-hydrazones or pyridyl-4-hydrazones of cyclohexanone and phenylhydrazinopyridines to give hydrogenated derivatives of diverse carboline ring systems. The Fischer reaction involves isomerisation of hydrazones into enhydrazines with subsequent [3, 3] sigmatropic rearrangement (concerted cleavage of the N-N bond and formation of a C-C bond) followed by the closure of pyrrole ring and loss of ammonia to give tetrahydrocarbolines [12, 13] .
A variety of carboline ring systems have been reported by Fischer reaction but the methods to synthesize -carbolines are scarce among the various methodologies reported. In this respect, Abramovitch and Adams reported the cyclization of cyclohexanone 3-pyridylhydrazone for the formation of a mixture of hydrogenated derivatives of -carboline 10 and smaller amount of -isomer 11 [14] . These isomers were dehydrogenated in good yields to afford aromatic tricyclic compounds 1 and 12 (Scheme 1).
Although this route provided a convenient and readily reproducible method to the synthesis of -carbolines, the Fischer reaction can further be utilised so that the potential of this method to prepare structurally diverse novel biologically active agents can be explored in depth. The synthesis of cryptolepine using Fisher reaction has not been reported yet. However, Dhanabal et al. [15] described the synthesis of isocryptolepine using this method as the key step.
Graebe-Ullmann Reaction
The Graebe-Ullmann reaction is an alternative method for synthesizing carbolines by which substituted pyridylbenzotriazoles or 1-phenyltriazolopyridines are prepared and are decomposed by various techniques including heat [16, 17] , microwave irradiation [18] , photolysis [19] , heating in phosphoric [20, 21] or polyphosphoric [18, [22] [23] [24] [25] [26] [27] [28] acids. Many research groups have explored this reaction for the synthesis of indoloquinolines using haloquinolines instead of halopyridines as one of the starting material. There have been many reports [29] [30] [31] for the synthesis of neocryptolepine derivatives ( -carboline analogs) using this reaction whereas the synthesis of cryptolepine derivatives ( -carboline analogs) using this reaction has not been reported. E. Spath and K. Eiter utilised this reaction for the first time to synthesize -carbolines. The first reaction is between ophenylenediamine and 3-bromopyridine in the presence of copper sulphate at 155°C for 9h resulting in N 1 -(pyridine-3-yl)benzene-1,2-diamine (13) , which was then transformed into 1-(pyridin-3-yl)-1H-benzo [d] [1, 2, 3] triazole (14) [32] , by treatment with nitrous acid (10% HCl, NaNO 2 ) at 10°C. Heating 14 with ZnCl 2 at 320°C afforded a mixture of -carboline 3 as the major product, andcarboline 1 as the minor product (Scheme 2).
K. Eiter and A. Nezval have performed a similar synthesis ofcarboline derivatives by using 3-bromopyridine and 3-methyl-ophenylenediamine [33] . The reaction proceeded with the synthesis of pyridyl-substituted benzotriazole which on heating with ZnCl 2 at 320°C gave a mixture of -carboline and -isomer. Later, R.A. Abramovith synthesized a mixture of -carboline 1 and its N-oxide 17 by the thermal decomposition of azide derivative 16 obtained from 2-(o-aminophenyl)pyridine N-oxide (15) (Scheme 3) [34] .
An analogous synthesis of -carboline 1 was performed through the thermal decomposition of azides (Scheme 4) [35] in the presence of decalin at 155-170°C.
Further, the ability to use azides for the synthesis ofcarbolines was studied and it was shown that the azide 18 can be transformed to -carboline 19 in good yield by refluxing in toluene (Scheme 5) [36] . 
Scheme 2.
An alternative method for synthesizing -carboline was employed by which N-methyl-N-(3-pyridyl)-o-phenylenediamine (20) was converted into a mixture of -carboline 22 as a major product and -carboline 23 by the formation of an intermediate 21 (Scheme 6). The transformation of the intermediate takes place in aqueous solution at room temperature in the presence of Cu powder. It was suggested that decomposition of intermediate takes place through a radical mechanism [37] .
Photochemical Cyclization
Photochemical cyclizations hold an advantage over thermal reactions since these cyclizations aid in the formation of thermodynamically disfavoured products. Photochemical conversions overcome activation barriers and allow reactivity which is otherwise difficult by thermal reactions. Photochemical cyclizations of anilinopyridines and anilinoquinolines have been reported for the synthesis of -carbolines and cryptolepine. Thus, Clark et al. have reported that the photochemical cyclization of 3-anilinopyridine in THF for 23 h give a mixture of -carboline 1 and -carboline 12 in yields of 40 and 19%, respectively (Scheme 7) [38] .
The synthesis of cryptolepine (2) in small amounts has been reported via heteroatom directed photoannulation technique. The anilinoquinoline (26) was synthesized in the first step by nucleo- philic substitution of 3-bromoquinoline (24) with aniline (25) at 200°C and was subjected to photochemical cyclization. Interestingly, both linearly-fused and angularly-fused products quindoline (3) and isoneocryptolepine (27) were obtained in 16 and 51% yield, respectively. Quindoline (3) on methylation gave cryptolepine (2) (Scheme 8) [39] .
Metal-complex Catalysed Annelation and Intramolecular Cyclization
Palladium catalysed amination and intramolecular cross coupling reactions have become a powerful tool for the interconversion of less reactive substrates. The palladium catalysed reactions such as Suzuki and Heck cross couplings have been extensively utilised by the medicinal/organic chemists to synthesize biologically active molecules at relatively low temperature. Other metal alternatives like copper or iron based catalyst are comparatively less active than palladium catalysts. A synthetic strategy applicable to all carbolines based on Pd-catalyzed amination and arylation of substituted pyridines has been developed [40] . Abiding with the title of the review, the strategy for -carboline synthesis has been represented as shown below (Scheme 9).
Thus, the reaction of iodobenzene (28) and 3-amino-2-bromopyridine (30) in the presence of Pd 2 (dba) 3 , 1,1'-bis(diphenylphosphino)ferrocene and t-BuONa in toluene at 100°C produced 2-bromo-(3-phenylamino)pyridine (31) in 64% yield. Analogously, 2-bromo-(2-bromophenylamino)pyridine (32) was prepared by reaction of 29 and 30 in 71% yield. Intramolecular arylation of 31 catalyzed by Pd(OAc) 2 in the presence of Na 2 CO 3 in DMF gave the corresponding -carboline 1 in 51% yield. The o,o'-Dibromophenyl aminopyridine (32) could be cyclised only through the corresponding N-methylsulfonyl derivative 33 into thecarboline 34 in 84% yield.
A series of novel studies were performed to synthesize carbolines using metallation reactions of substituted pyridines and further targeted cyclizations [41, 42] . Thus, reaction of oacylaminophenylboronic acids with dihalopyridines 35 formed arylpyridine intermediate 36, which upon heating with pyridinium chloride produced -carboline (1) in 78% yield (Scheme 10). Later, an extension of this method for the synthesis ofsubstituted -carbolines (37) was developed and published by the same group. (Scheme 11) [43] .
Similar synthesis involving the reaction of substituted dihalopyridines with electrophilic reagents and an unexpected migration of the halogen atom in the pyridine ring has been reported [44] . The intermediate compounds 38 & 39 were synthesized using Suzuki or Stille coupling reactions which underwent cyclization to afford target -carbolines (40) (Scheme 12).
, -Biscarboline 41 was synthesized in the same study by an analogous method (Scheme 13) [44] .
The aforementioned series of synthetic strategies have also been utilised for the synthesis of benzocarbolines (quindolines). For example, Pd-catalyzed cross-coupling reaction between acyl aminophenyl boronic acid and 3-fluoro-2-iodoquinoline derivatives afforded aryl haloquinoline intermediates 42 which underwent cyclization on treatment with boiling pyridinium hydrochloride to give benzo--carboline derivatives 43 in 51-83% yield. (Scheme 14) [45]. The reactions were carried out by typical Suzuki procedures [46] [47] [48] [49] . The intramolecular nucleophilic displacement of fluorine with amino group is facilitated by the formation of quinoline hydrochloride [41] .
Further, the synthesis of 10H-indolo[3,2-b]quinoline (3) has been reported in which 3-bromoquinoline (44) was first converted to N-phenylquinolin-3-amine by N-arylation. The reaction was carried out at room temperature in the presence of triphenylbismuth diacetate and metallic copper. The resultant N-phenylquinolin-3-amine (45) undergoes oxidative cyclization in the presence of palladium acetate and trifluoroacetic acid at 90°C to give 3 in 23% yield (Scheme 15) [50] .
10H-Indolo [3,2-b] quinoline and 7H-indolo[2,3-c]quinoline derivatives have also been synthesized using a modified approach to the earlier reported method. The first step involved a copper acetate-catalyzed coupling reaction between commercially available 3-aminoquinoline and phenylboronic acid derivatives and the second step utilized a palladium acetate-catalyzed intramolecular arylation reaction in the presence of trifluoroacetic acid as solvent [51] (Scheme 16).
Further, considering the fact that -heteroaryl halogen atom is more reactive than the -halogen atom [52] , the synthesis of quindoline (3) was accomplished [53] by a regioselective coupling reaction of 2,3-dibromoquinoline (51) with boronic acid 52 to give Npivaloyl-2-(2'-anilino)-3-bromoquinoline which on hydrolysis gave the free amine 53. The free amine 53 then underwent cyclization at 200-220°C in presence of pyridinium hydrochloride to give quindoline (3) (Scheme 17).
Recently, the synthesis of 11-alkylated cryptolepines via radical cyclization and Stille coupling reaction has been reported [54] gave the 2,4-disustituted-3-fluoroquinolines 56 which on cyclization followed by methylation resulted in 11-n-butyl and 11-isopropyl cryptolepines 58.
The first thieno--carboline 61 was prepared in 70% yield by intramolecular palladium-assisted cyclization of an ochlorodiarylamine. The later was in turn selectively synthesized in 90% yield by C-N palladium catalyzed cross-coupling of 3-bromo-2-chloropyridine with 6-amino- palladium-catalyzed conversion into -carbolines 81-83 in 63-88% yield [57] . The reactions involve intramolecular additions of arylpalladium to the cyano group and subsequent processes such as hydrolysis, electrocyclization, ethyl group transfer and oxidative aromatization (Scheme 21).
A green and efficient preparation of functionalized -carbolines via reductive ring closure by 1,2-bis(dipenylphosphino)ethane under solvent-free conditions has been recently reported [58] . In the first step, 3-nitro-2-phenylpyridines/2-nitrobiphenyl intermediates 84-92 were readily prepared through Suzuki-Miyaura crosscoupling reaction from phenyl boronic acids and 2-chloro-3-nitropyridine. These intermediates were then subjected to Cadogan cyclization to obtain various substituted -carbolines. The polar byproduct ethane-1,2-diylbis(diphenylphosphine oxide) was removed from the relatively polar reaction mixture. The substrates with electron-withdrawing groups (EWG) also gave the desired products in good yield (Scheme 22).
-Carboline Synthesis Based on Indole Derivatives
S.Yu. Ryabova et al. reported an approach to the synthesis ofcarbolines based on acetylindoxyl (102) in which acetylindoxyl was first reacted with p-nitrophenylaniline in a two-step synthesis to afford 3-p-nitrophenylaminoindole (103) , which undergoes a Vilsmeier reaction resulting in the formation of 2-formyl-3-pnitrophenylaminoindole (104) [59] . Further, 104 reacts with malondinitrile resulting in the corresponding 2-dicyanovinylindole derivative 105, which when refluxed in 1:1 ratio DMF:MeOH gives 1-p-nitrophenyl-2-imino-3-cyano-1,2-dihydro--carboline (106) in 73% yield (Scheme 23). This compound is in tautomeric equilibrium with amine derivative 107 as per their PMR spectra.
In analogy with the aforementioned reactions, 104 has been reacted with other compounds containing an active methylene group [60] . Reaction of 104 and cyanacetamide or cyanacetic ester produced vinyl derivatives 108a and b. However, an attempt to cyclize these compounds by heating in DMF:MeOH was unsuccessful because of steric hindrance caused by replacing a cyano group by bulky carbamide or ethoxycarbonyl groups. Cyclization of 108a and b was affected by heating them in trifluoroacetic acid. Subsequent treatment of the intermediate trifluoroacetates 109a and b with K 2 CO 3 produced -carbolines 110a and b (Scheme 24). In both instances the pyridine ring was closed with involvement of the cyano substituent. densations with CH-acids was also studied [61] . As it turned out, the condensation of 111 occurred much more easily than for 104 because of the presence of the unit positive charge. The immonium salt reacted with malonodinitrile, cyanacetamide, and cyanacetic ester even at room temperature and did not require the prolonged heating of the reagents like 104.
The main product obtained by refluxing 111 and acetoacetic ester in i-PrOH was carbolinium chloride 112, treatment of which by base produced 1-p-nitrophenyl-2-methyl-3-ethoxycarbonyl--carboline (114) in 39% yield. A side product of the bis-derivative 113 was isolated in 7% yield. The reaction occurred differently for 104. Refluxing in i-PrOH formed exclusively 115 whereas heating in pyridine produced -carboline 114 in 40% yield (Scheme 25) [60] .
Another interesting -carboline synthesis has been developed based on 3-(N'-phenyl-N'--chloroacetyl)amino-2-formylindole (116) [62] . Reacting 116 with pyridine formed an intermediate pyridinium salt (117) in which the methylene had highly acidic CH bonds. As a result, spontaneous intramolecular cyclization involving the formyl group occurred to form carbolinone 118. Treatment of 118 with benzylamine in MeOH resulted in opening of the pyridinium ring and formation of 3-amino-2-oxo-1-phenyl-1,2-dihydropyrido[3,2-b]indole (119) (Scheme 26).
-Carbolines were also synthesized starting from oximes of 3-acetylindoles 120, which underwent rearrangement into 3-acylaminoindoles 121 upon refluxing in acetic acid. Compound 121 was then reacted with a synthetic equivalent of -dicarbonyl 122 to give tricyclic compounds 123a and b (Scheme 27) [63] . A convenient synthesis of -carbolines has been developed based on indol-3-aldehydes 124a-c [64] . Reacting 124a-c and hydroxylamine derivatives resulted in a series of -(indol-3-yl)nitrones 126 that were then converted by reaction with sodium malonic ester into substituted esters of N,N-aryl(indol-3-yl)--aminopropenoic acids 127. The resulting compounds were transformed by treatment with acetic or trifluoroacetic anhydride into oxo -carboline derivatives 127 (Scheme 28).
The synthesis of quindoline (3) have been described by Cooper et al. using intramolecular -nucleophilic substitution reaction wherein the intermediate 129 was prepared by indole derivative 128 using direct lithiation and addition of 2-nitrobenzaldehyde with subsequent oxidation with MnO 2 . Further, 129 was converted to amido ketone 130 by catalytic hydrogenation and N-benzoylation using benzoylchloride. The cyclised product 131 was obtained from 130 in 80% yield in the presence of catalytic amount of sodium hydride. N-deprotection of 131 using NaOH in MeOH and subsequent reaction with POCl 3 followed by catalytic hydrogenolysis of the resultant chlorinated compound 133 afforded quindoline (3) in 95% yield (Scheme 29) [65] .
Bierer et al. have reported [66, 67] the synthesis of cryptolepine and its analogues by using the procedures reported by Holt and Petrow [68] and Degutis and Ezerskaite [69] (Scheme 30). Substituted indolyl acetates 134 was reacted with isatin derivatives 135 to give respective quindoline carboxylic acids 136-140 which on heating at 255°C in Ph 2 O resulted in quindolines 141-145. The resulted quindolines were alkylated using the method of Fichter and Boehringer [70] to give the respective cryptolepines 146-150. All these compounds were evaluated for their in vitro antihyperglycemic activities in non-insulin-dependent diabetes mellitus (NIDDM) mouse model. Several other investigators have reported the synthesis of cryptolepine analogues using the above methodology [2, 67] and screened them for their antimalarial and cytotoxic activities [71, 72] .
Bierer et al. have reported the synthesis of 4-methoxy cryptolepine hydrochloride and evaluated it for its antimalarial and antihyperglycemic activities [67] . Condensation of indole derivative 102 with 3-methoxy-2-nitrobenzaldehyde using piperidine and molecular sieves at room temperature afforded 151 as a mixture of E/Z isomers which on reduction, deprotection and subsequent alkylation afforded the methoxy cryptolepine hydrochloride (154) (Scheme 31).
An efficient synthesis toward highly diversified -carbolines via one-pot multicomponent reaction using N-Boc-3-amido indoles, aryl aldehydes, and aromatic terminal alkynes under microwave conditions (90°C) for 1.5h has been described (Scheme 32) [73] . The reaction took place in the presence of 30% TFA in ACN giving 52-75% yield of -carbolines.
In another scheme, Diels Alder reaction of ethyl vinyl ether with , -ethylenic ketone 157 have been reported. The reaction took place in the presence of ytterbium(III) as Yb(fod) 3 at 100°C in a sealed tube to yield 64-91% ethoxypyrans 158 as a mixture of diastereomers in a ratio 86:14 (trans:cis). Further, reaction of each form, trans and cis, in the presence of hydroxylamine HCl and ACN at 82°C yielded 67-85% of each form of -carbolines 159 (Scheme 33) [74] .
The complex obtained from dimethylformamide and POCl 3 acts on 3-aminoindole (160) introducing the formyl and amidine moieties at C-2 and C-3 of the indole ring with the formation of acetami- 161 which further in the presence of vilsmeier's reagent and POCl 3 yields -carboline 162 (Scheme 34) [75] .
3-(2-Acetyl-l,3-dioxobutylamino)indole (164) obtained by reaction of 163 with sodium acetylacetonate, was reported to readily cyclize to 2-hydroxy-4-methyl-5H-pyrido [2,3-b] indole (165) when it is heated in alkali (94% yield) or treated with concentrated hydrochloric acid (72% yield). Compound 165 forms an O-acetyl derivative 167 when it is heated in acetic anhydride (Scheme 35) [76] .
The reaction of 3-acetylindole oxime (168) with acetylene in the KOH/DMSO at 120 °C for 1 h, at 20-25 atm, unexpectedly afforded 2-methyl-5-vinylpyrido [3,2-b] indole (4-methyl-1-vinyl--carboline) (169) in 40% yield, along with the expected 1-vinyl-3-(1'-vinyl-2'-pyrrolyl)indole (170) in 6% yield (Scheme 36). When carried out at atmospheric pressure (120 °C, 5 h), the reaction lead mainly to 3-acetyl-1-vinylindole (171) in 26% yield, with thecarboline 169 and pyrrolylindole 170 being minor products (9% and 17%, respectively). Interestingly, the other 3-acylindole oximes, when reacted with acetylene under conditions close to the employed in this work, did not give any carbolines, but only the expected Ovinyloximes and 3-pyrrolylindoles [77] .
The 1,5-dicarbonyl compounds (A) were synthesized in 28-70% yield by the addition of 1-acetyl-3-indolinone (172) to , -unsaturated carbonyl compounds and further cyclization of 1,5-dicarbonyl compounds in the presence of acetic acid and excess ammonium acetate gave -carbolines 173 in 30-50% yield (Scheme 37) [78] . which on refluxing with PCl 5 afforded the chloro compound 178 in 70% yield. The compound 177 may also have formed by intramolecular 1,4-addition, following expulsion of nitro group and subsequent N-deprotection of carboethoxy group.
Other Miscellaneous Methods
The synthesis of a series of 11-chlorocryptolepine analogs and their evaluation for antimalarial and antihyperglycemic activities has been reported by Bierer et al. (Scheme 39) [67] . Intermediates 180 (a-d) were synthesized by reacting anthranilic acids 179 (a-d) and bromoacetyl bromide in DMF at room temperature. These intermediates on treatment with substituted aniline derivatives at 120°C gave the anthranilic acid derivatives 181 (a-i) which cyclises in the presence of PPA to give quindolones 182 (a-i). These quindolines on refluxing with POCl 3 afforded 11-chloroquindolines 183 (a-i). N-Methylation of 183 was achieved using methyl triflate to give the respective hydrotriflate salts which was converted to free base and subsequent treatment with HCl afforded the corresponding 11-chlorocryptolepine hydrochloride salts (Scheme 39).
Dutta et al., have reported the synthesis of various 2-substituted cryptolepines using regioselective thermal cyclization and reductive cyclization using triethyl phosphite (Scheme 40) [81] . 2-Nitroacetophenone (184) when treated with POCl 3 in DMF gave the -chlorocinnamaldehyde derivative 185, which on reaction with excess arylamines in the presence of 2N ethanolic HCl afforded the corresponding enaminoimine hydrochlorides 186. The intermediates 186 at 200-250°C gave the respective 2-(2-nitrophenyl)quinoline derivatives 187 which on heating with triethyl phosphite at 160°C prepared the quindolines 188.
An interesting synthesis of carbolines that gave product mixtures including -carbolines (191) and -carbolines (192) was based on the reaction of 2,3,5,6-tetrachloro-4-cyanopyridine (190) with enamines in refluxing chlorobenzene [82] . Hydrogenated derivatives of carbolines 191 and 192 were formed in the reaction which readily aromatized by dehydrogenation using dichlorodicyanoquinone in refluxing chlorobenzene. It was shown that the structures of the starting enamines had a significant influence on the ratio of carbolines in the product mixture (Scheme 41). volved the reduction of nitro groups with Fe powder followed by oxidative cyclization and subsequent N-methylation.
Recently, J.K. Laha et al. have reported the synthesis of carbolines by photostimulated unimolecular radical nucleophilic substitution (S RN 1) cyclization of anilinohalopyridines in the presence of potassium t-butoxide (KOBu t ) and liquid ammonia or dimethyl sulfoxide (DMSO) (Scheme 43) [84] .
PHARMACOLOGY AND SPECTRAL STUDIES
Several investigators have reported the pharmacological effects of -carbolines (Table 1) in prokaryotic and eukaryotic cells partially because of their ability to interact with DNA and alter its replication process or because of their action on enzymes involved in DNA repair process. Initially Kirby et al. after preliminary absorption measurements suggested that cryptolepine interacts with DNA [85] . However, the exact mode of action of cryptolepine was unknown until Bonjean et al. reported that cryptolepine interferes with topoisomerase II and inhibits primarily the DNA synthesis in B16 Melanoma cells 4-5 times more than ellipticine [86] . Cryptolepine reacted with DNA by intercalation (Fig. (3) ), resulting in a marked red shift and hypochromism of the absorption spectra and a negative reduced dichroism indicating that quinoloindole chromophore is oriented parallel to the DNA base pairs. Cryptolepine was also reported to induce cleavage of poly(ADP)ribose polymerase and apoptosis via Caspase-3 activation [87] . Zhu et al. reported that cryptolepine activates different molecular pathways to inhibit cell cycle progression in a dose dependent manner i.e. G1 phase arrest at 1.25-2.5μM, S phase and G2/M phase arrest at 5μM and an increased subG1 phase at 10μM in human lung adenocarcinoma A549 cells. Various spectral studies have been performed to evaluate the cryptolepine-DNA complex including ESI-MS and ESI-MSMS [88] . It has also been reported that the potential use of cryptolepine derivatives in chemotherapy could lead to genotoxicity [89] . In fact recently, G-Quadruplex DNA ligands NSC748392, NSC748393 and NSC748394 (Fig. (4) ) with drug like properties were designed and reported, but only NSC748393 showed promising in vivo results [90] .
FUTURE PERSPECTIVES AND HYPOTHESIS: A NEW CHEMICAL LADDER IN SEARCH OF NOVEL DRUGS
2,5-Pyrrolidinedione (succinimide) or 2-pyrrolidone fused polycyclic (hetero)aromatic molecules are of great interest as the succinimide part of fused polycyclic heteroaromatic molecules can interact with the ATP binding pocket via an hydrogen-bonds network with some selectivity towards specific enzymes especially kinases and topoisomerases [91] . Various heterocycles like carbazoles [92] , -carbolines [91] , -carbolines [93] and -carbolines [94] have been reported with linearly or angularly fused 2,5-pyrrolidinedione or 2-pyrrolidone derivatives as potential and specific ligands for proteins involved in cancer pathogenesis and various other pathogenic conditions. Further, -carbolines being the least addressed molecules have never been fused with 2,5-pyrrolidinedione or 2-pyrrolidone derivatives partially due to the lack of expedient methods for their synthesis. All the known methods give functionalized basic scaffold representatives of this family with low to moderate yield. In fact, only recently the first thieno-- carboline synthesis was reported in good yield by C-N palladium catalyzed cross-coupling and intramolecular palladium catalyzed cyclization [55] . Apart from this, there are no reports available for the synthesis of fused polycyclic heteroaromatic--carbolines. Future research should, therefore, pay more attention to novel heteroannulated -carbolines with fused 2,5-pyrrolidinedione or 2-pyrrolidone derivatives. Based on the literature review, we propose linear and angularly fused 2,5-pyrrolidinedione and 2-pyrrolidone -carbolines I-IV (Fig. (5) ).
These novel pyrrolo--carbolines may be produced by the retrosynthetic schemes like 44 and 45. According to this hypothesis, 3-and 4-halogen or 3-and 4-amino substituted phthalimide analogues structurally related to thalidomide may be synthesized. Further, these analogues may be utilised to synthesize ortho-halogen substituted diarylamines by C-N palladium catalyzed cross-coupling (Buchwald-Hartwig) with 3-amino-2-bromopyridine or 3-iodo-2-bromopyridine or 3-bromo-2-chloropyridine. The formed orthohalogen substituted diarylamine intermediates may be subjected to intramolecular palladium-assisted cyclization (intramolecular Heck cross coupling) to obtain novel pyrrolo--carbolines. Work in this direction is in progress in our laboratories.
We ensure that a huge chemical space is available amongcarbolines which, if explored properly, may open up the new avenues for further research in chemistry and biology of heteroannulated -carbolines. The synthesis of linear and angularly fused 2,5-pyrrolidinedione or 2-pyrrolidone -carbolines may possibly occupy to some extent this chemical space. These hypothetical molecules may develop as novel hits and leads to target various proteins involved in the pathogenesis of various diseases.
CONCLUSION
The various synthetic methods for -carbolines have been reviewed. The routes of characteristic synthesis of the -carboline compounds seem to be more or less similar. If useful compounds are to be found in this series, novel approaches to synthesize fused polycyclic (hetero)aromatic--carbolines, structurally related to other carbolines and carbazoles, have to be developed. This may provide a new chemical ladder towards the development of chemistry and biology of -carbolines in search of novel drugs.
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INTRODUCTION
Lentivirus forms a distinctive genus of pathogens, which affects wide range of animals, including humans. The prefix 'lenti' (lento means slow) represents prolonged incubation without clinical symptoms, persistent viral replication, neurologic manifestations, and destruction of specific hematologic or immunologic cells leading to a chronic progression and death. Human immunodeficiency virus (HIV) belongs to a family of primate lentiviruses and is of two distinct subtypes namely, HIV-1 and HIV-2 [1] . HIV-1 is the most notorious and globally important lentivirus whereas HIV-2 has been isolated primarily in West African countries such as Guinea Bissau, Ivory Coast, and Senegal, With some cases also identified in America and Western Europe. Both agents are associated with the development of progressive immunologic deterioration which causes a dramatic decline in the number of CD4 + T lymphocytes [2] and when the number of these cells becomes low enough, neurologic abnormalities, and opportunistic infections arise forming the pathological basis for acquired immunodeficiency syndrome (AIDS) in humans (Fig. (1) ). However, epidemiologic studies suggest that the incubation period for HIV-2 for the development of disease is longer than for HIV-1 [3] . 
HIV Infection
HIV is transmitted by direct sexual contact, either homosexual or heterosexual, by blood or blood products and from an infected mother to infant, either intrapartum, perinatally, or via breast milk [4] . Primary infection of humans with HIV-1 is associated with an acute mononucleosis-like clinical syndrome ( Table 1) which appears approximately 3-6 weeks following infection. However, HIV-2 is not as easily transmitted perinatally as HIV-1 [5] . Although HIV has been reported to infect a wide range of cells like B cells, natural killer cells, eosinophils, precursor CD4 + bone marrow cells, CD8 + T cells, renal epithelial cells, cervical cells, columnar epithelial cells, as well as cells and tissues from various organs like liver, lungs, salivary glands, eyes, prostate, and testes but CD4 + T lymphocytes and macrophage-lineage cells are consistently found to be infected with HIV [6, 7] .
Overview of HIV Replication
HIV replication is a multi-step complex process, which involves attachment of the viral membrane protein to the cellular receptor (CD4) and co-receptors (CCR5, CXCR4) of the host cell membrane. Following this attachment, fusion peptide brings the host and viral membranes into close proximity creating a fusion pore and allowing entry of the HIV capsid into the host cell [8] . After entering the cytoplasm, reverse transcription begins and the preintegration complex is integrated into the host genome (Chromosomal DNA). New virus particles are produced by further transcription of new viral RNAs, which give rise to new envelope proteins. Viral core proteins are synthesised in Fig. (1) . A schematic diagram of the pathogenic events that occur from initial infection with HIV to the development of clinical disease. 
Lymphoma (mostly EBV, some HHV-8)
pure sensory ataxia, paresthesia/dysesthesia, peripheral neuropathies such as acute demyelinating polyneuropathy, mononeuritis multiplex, and distal symmetric polyneuropathy, myopathy , AIDS dementia complex the cytoplasm and simultaneously assembly of new virions occurs at the plasma membrane immediately before release of new virions. Then budding takes place and these viral proteins are processed into the individual components by the viral protease (Fig. (2) ) [9] .
Mechanisms of CD4 + T Lymphocyte Dysfunction
One of the early hallmarks of HIV infection is the impairment of a variety of CD4 + T-cell functions including T-cell colony formation, autologous mixed lymphocyte reactions, expression of interleukin-2 (IL-2) receptors, and IL-2 production [10] . Further, the T-cell proliferative response is lost to recall the antigens such as tetanus toxoid, influenza, Candida albicans, alloantigens and subsequently mitogens [11] . The cell surface expression of the CD4 receptor in infected CD4 + T cells is down-regulated as the HIV gp120 molecules produced during viral replication bind to cytoplasmic CD4, forming intracellular gp120-CD4 complexes. Other viral products, Nef and Vpu, also contribute to the down regulation of CD4 [12] [13] [14] [15] [16] [17] [18] causing a decline in antigen-specific responses. Failure to respond to antigenic stimuli has also been seen in uninfected CD4 + T cells in HIV-infected patients [19, 20] . HIV proteins such as purified Env glycoproteins (both HIV gp120 and gp41), Env peptides, and purified Tat protein have been reported to suppress, in vitro, proliferative responses to mitogens, antigens, and anti-CD3 antibody. Exposure of cells to HIV gp120 also inhibits both IL-2 production and IL-2 receptor expression. A number of possible mechanisms by which viral replication occur are: 1. The virus mutates rapidly and the resulting mutants can escape the neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses. 2. The virus replicates in immunologically privileged sites where in the macrophage may limit the viral expression while effectively disseminating it [21] . 3. The presence of glycosylation sites on the Env proteins suggests that the virus becomes invisible to the immune system by using carbohydrates as a protective shield against the host's immune response [22] [23] [24] . Mutations in gag and pol allow the virus to escape from the cellular immune responses. CTLs are reactive against a specific viral sequence but are ineffective at controlling infection in an infected individual with virus expressing the same sequence.
The reason for this is not yet clear. In addition, the complex replication cycle of the HIV leads to high-level viral production before being detected as foreign.
Viral Load and Progression to Disease
It is important to point out the difference between longterm non-progression of HIV disease and long-term survival. Long-term survivors are patients who although infected for 10 or more years are still alive, but whose HIV disease may or may not have progressed with regard to deterioration of their immune systems. Long-term non-progressors are those HIV-infected individuals who not only have survived 10-15 years of HIV infection, but are also free of symptoms and have CD4 + T cell counts that have remained stable and reasonably normal. The genetic defects in the infecting virus may play a part in long-term non-progression. One patient was found to have a defect in nef gene [25] . Out of seven blood recipients from a donor of the infected virus that had sustained deletions in the nef gene, six remained free of AIDS and had stable and normal CD4 + T-cell counts even after 10-14 years of infection. Virus obtained from these recipients had nef gene deletions [26] . This shows that the alterations of nef might be responsible for long-term nonprogression of the disease. Adult rhesus monkeys were infected with cloned virus in which the nef gene was partially deleted. They showed very low levels of viremia analogous to the human long-term non-progressors and did not progress to disease [27, 28] . This suggests that nef gene is not necessary to establish or maintain infection, but it is required for high viral load. The mechanisms that underlie this effect are not yet understood [29, 30] . Nef protein seems to be required for efficient replication, increase cell division and expand the numbers of cells available for productive infection in vivo. The highly virulent SIVsmmPBj14 strain derives its pathogenicity from a point mutation in nef gene that may increase its interaction with cellular kinases [31, 32] . CD8 + T-cell counts remain high in long-term survivors but decline during disease progression [33] . Non-progressors who maintain high levels of CD8 + T-cell responses carry relatively non-cytopathic variants of HIV; such variants have a restricted cell tropism and grow to low titer in cells in vitro [34, 35] . The low titer may reflect selection for viral variants with greater resistance to the immune response. Variation in rate of disease progression may also reflect genetic variation in the host. Consistent with this idea, it has been reported that HIV-infected individuals who are heterozygous for a 32-base deletion in the CCR5 gene have slower rate of progression to AIDS [36, 37] . Genetic diversity in the variable regions of env is noticeably less in rapid progressors [38, 39] . This might mean that a less virulent virus variant is also less fit and therefore that there are more mutations that confer a positive selective benefit.
TARGETS FOR ANTIRETROVIRAL THERAPY
There are currently 6 different targets for antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) infection. These include envelope (entry and fusion), integrase, reverse transcriptase and protease [40] . In addition to these essential viral enzymes that have been extensively explored as targets for antiretroviral drugs, a diverse array of potential targets for the development of new classes of HIV therapies have been reviewed that included Vif-APOBEC3G [41, 42] , Integrase-LEDGF/p75 [43] , TRIM5 [44, 45] , virus assembly and maturation, and Vpu [46, 47] .
Viral Entry: (Receptor Binding and Fusion with Cells)
The primary receptor for HIV is CD4, which is present on the surface of CD4 + T lymphocytes, and certain other cells [48, 49] . In addition to its role as the principal receptor for HIV, CD4 serves as an adhesion molecule to stabilize the interaction. The entry of virus into host cells is a multi-step process including attachment to host cells and CD4 binding, coreceptor binding, and membrane fusion. All of these steps are mediated by the noncovalently associated viral envelope (Env) proteins, gp120 and gp41. The gp120 subunit of Env mediates attachment, CD4 binding, and coreceptor binding, and consists of five conserved (C1-C5) and five variable (V1-V5) domains. These domains are critical for binding to host cells. The gp41 subunit of Env is responsible for the membrane fusion. Although HIV can bind to CD4 on cells, fusion between the HIV envelope and the cell membrane fails to occur, indicating the absence of a cell surface component essential for fusion [50] . The host-cell component (coreceptor) referred to as the "fusion receptor" permits HIV infection of mammalian cell that expresses CD4 [51] . The two most important coreceptors are CXCR4 (also called fusin or LESTR) and CCR5 (Fig. (3) & Fig. (4) ) [52] . Coreceptors not only provide a crucial function for viral entry into cells, but they are also the principal determinants of tropism among CD4 + cells. The chemokines that can bind to these receptors can block HIV-1 infection, and a defect in the gene encoding CCR5 causes natural resistance to HIV infection [53] .
The entry sites for pH-independent viruses, such as HIV-1, have long been assumed to fuse directly with the plasma membrane, whereas enveloped viruses that rely on a low pHdependent step for entry initiate infection by fusing with acidic endosomes. Fusion of HIV-1 with the plasma membrane did not progress beyond the lipid mixing step at the cell surface. The failure beyond this step indicates that the formation and/or dilation of a fusion pore depend on pH. The lack of complete fusion at the cell surface could be due to restrictions imposed by the cortical actin or other factors present in or around the plasma membrane. An alternative possibility is that viruses rely on yet unidentified endosomal factors to promote complete fusion. Miyauchi et al. recently reported that HIV-1 also opt for the endocytic machinery to enter into and fuse with target cells. A novel role for dynamins in HIV-1 content release from endosomes has been reported. The ability of dynamin to regulate actin Fig. (3) . Binding of HIV gp120 to the host cell CD4. A. Virus entry into host cells mediated by glycoprotein. The functional unit is a trimer of covalently bonded gp41 (yellow bars) molecules and gp120 (majenta spheres) molecules. B. Second step is the binding of gp120 to host cell CD4 (Blue squares) resulting in the reconfiguration of gp120 molecule. C. CD4-bound gp120 interact with the coreceptor, either CCR5 or CXCR4 with the formation of ternary complex. Fig. (4) . Membrane fusion of HIV to release viral core in cytoplasm of host cell. In this step the insertion of gp41 in to the host cell membrane with the formation of a bridge between viral and cellular membrane occurs. Metastable prefusion takes place with the formation of a six-helix bundle and with the close approximation of the membranes a fusion pore is formed, which enlarges to release the viral core in to the cytoplasm. remodelling and/or to associate with membrane-bending proteins could provide an additional driving force to expand pores and permit the release of the HIV-1 core. Endocytic entry offers several advantages, including the sheltering of HIV-1 from antibodies and inhibitors targeting intermediate conformations of Env during the unusually slow fusion reaction [54] .
Integrase-LEDGF/p75 Axis
As per the co-crystal structure (PDB Id 2BJ4) of the interacting domains of integrase and LEDGF/p75, LEDGF/p75 is a protein with 533 amino acids which while interacting with HIV-1 integrase, a highly conserved integrase binding domain (IBD) is present in the C-terminus (amino acids 347-429) of HIV-1 integrase whose two monomers interacts with a dimer of the catalytic core domain (CCD) of integrase at an interhelical loop of "LEDGF/p75". The most critical interacting residues of the IBD are I365, D366 and F406 [55, 56] . Further, to establish the role of LEDGF/p75 in the replication of HIV-1, many cellular and biochemical experiments were performed like reduction of HIV-1 integration in homozygous LEDGF disrupted murine cells. Mutagenesis studies like substitution of integrase amino acids with alanine diminished the interaction with LEDGF/p75 and showed that LEDGF/p75 is an important integrase cofactor which plays an active part in HIV-1 replication at the step of integration and proved this LEDGF/p75-integrase interaction as a novel target for antiviral therapy. Thus, small molecules that can enter the binding pocket in integrase, may prevent the interaction with the cofactor and will provide a vast momentum to this field [57] . However, during replication the majority of HIV-1 DNA remains unintegrated (uDNA) and is generally considered a replication dead-end. But recently, Gelderblom, H. C. et al. has reported that virus alternatively replicates by coinfection with integrating and non-integrating HIV-1 resulting in a several fold increase in the number of cells displaying uDNA early gene expression and efficiently driving uDNA into late gene expression. Further it was reported that uDNA-derived genomes undergo recombination with the integrated provirus-derived genomes during second round infection and generates virions by viral complementation. This novel mode of retroviral replication allows survival of viruses which would increase the replicating HIV-1 gene pool [58] [59] [60] .
Reverse Transcriptase
HIV are enveloped viruses that have RNA as their genetic material and utilize the enzyme reverse transcriptase (RNA-directed DNA polymerase) for the transcription of RNA genome into its complimentary DNA strand to form a double-stranded DNA:RNA hybrid which further gets transcribed into a double-stranded DNA copy of the HIV genome and gets incorporated into the human genome through the actions of HIV integrase enzyme.
Protease
Newly formed HIV particles are not infectious until they undergo ''maturation phase.'' This phase involves the cleavage of viral protein precursors by HIV protease enzymes which are encoded by HIV and offer an attractive target to design and develop drugs against maturation phase of HIV. These protease enzymes are symmetrical in nature. The structure shows a dimer with a central core that binds the peptides which are to be tailored by the enzyme [61] .
Vif-APOBEC3G Axis
APOBEC (apolipoprotein B mRNA-editing catalytic polypeptide) proteins are a group of cytidine deaminases, which include APOBEC1 (A1), AID, APOBEC2 (A2), APOBEC3 (A3), and APOBEC4 (A4), proteins in humans. All of these proteins contain one or two Zn 2+ binding motifs which catalyze cytidine deamination. These proteins target cytosines and convert them to uracils (C to U) on a variety of vertebrate-specific RNA/DNA targets. Further, A3 gene is a tandem arrayed cluster of genes encoding seven cytidine deaminase, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3DE, APOBEC3F, APOBEC3G, and APOBEC3H. The function of the A3 genes remained unknown until it was discovered that human APOBEC3G (A3G) inhibits human immunodeficiency virus type 1 (HIV-1) replication [62] [63] [64] . In the later phase of the viral life cycle, a 23-kDa phosphoprotein, "Vif" (viral infectivity factor) is expressed which directly binds to an anti-HIV factor, APOBEC3G (A3G) a single-strand DNA deoxycytidine deaminase [65, 66] , leading to its polyubiquitination and subsequent degradation by the 26S proteasome [67] [68] [69] . There are two important Vif domains, i.e, the central hydrophilic domain with amino acids 88 to 93 and the proline-rich domain with amino acids 161 to 164. These domains are essential to maintain the level of Vif function and to interact with tyrosine kinase [70, 71] . As a result of these activities, the concentration of A3G is effectively reduced from the infected cells leading to full infectivity of viral progeny. Therefore, when viruses lack this Vif functional gene they do not replicate in CD4 + T-cells and macrophage. When cells are infected by viruses without Vif, A3G is effectively incorporated into budding HIV-1 virions. Incorporation of A3G molecules into HIV-1 virions inhibits its replication during the next round of infection therefore Vif-A3G axis can be regarded as a new drug target for designing smallmolecule selective inhibitors of HIV-1 Vif to prevent Vifmediated ubiquitination of A3G and its degradation by proteasome. However, there are certain potential drawbacks also to this approach. In the complete absence of Vif expression, APOBEC3 is incorporated into HIV-1 virions and the viral genome undergoes hypermutation (extensive Gto-A mutation), rendering it non-viable in a single replicative cycle. Although a highly effective Vif inhibitor may result in mutational meltdown of the viral quasispecies, a partially effective Vif inhibitor may accelerate the evolution of drug resistance and immune escape due to the codon structure and recombinogenic nature of HIV-1 (72) (73) (74) . Therefore, further investigation is required to facilitate the rational design of such inhibitors.
TRIM 5 rh Factor
TRIM5 rh is a cellular factor that recognises the incoming viral capsid core structure and blocks HIV-1 infection at a post-entry, pre-integration stage in the viral life cycle (Fig. (2) ) and was first identified in a Rhesus monkey [75] . It is a member of TRIpartite Motif (TRIM) family of proteins and is comprised of a RING, a B-box, coiled-coil motifs (RBCC) and a B30.2 (PRYSPRY) domain which determine the potency and specificity for post-entry restriction and works against the late phase of HIV-1 replication for AIDS gene therapy [76] . For example, transgenic macrophages with high resistance to HIV-1 infection have been generated by introducing TRIM5 into hematopoietic stem cells proving this therapy an important application to treat HIV-1 and AIDS [77] . TRIM5 mediated antiviral therapy can be utilised for cost-effective HIV-1 therapy by synthesis of efficient peptidomimics, which can mimic TRIM5 rh protein. For example, It is reported that the removal of arginine 332 allows human TRIM5 to bind human immunodeficiency virus capsids and to restrict the infection [78, 79] . Mutation or change in the conformation of TRIM5 rh, which can mimic original protein or by increasing the in vivo expression of endogenous TRIM5 rh by interferon-like small molecules could also be alternative approaches [80, 81] but unfortunately interferon technique is not so active and could lead to toxicity [82, 83] . Since studies have shown that TRIM family proteins have anti-HIV-1 activity therefore designed TRIM family protein analogs may be used for future HIV-1 therapy.
Vpu Protein
Vpu is a small transmembrane protein of HIV-1 with a short amino terminal domain, transmembrane domain and cytoplasmic domain, which is translated from the same mRNA that encodes the envelope glycoprotein of HIV-1 [84] . It contains two kinase sites in the hinge region, which functions for the degradation of CD4 [85] . It interacts with the CD4 receptor in the rough endoplasmic reticulum (RER) and shunts it to proteasome for degradation [86] . The Vpu protein has a property to form an ion channel, "viroporins" and thus it also function to release virions from the cells through the transmembrane (TM) domain and ion channel. M2 protein of influenza is a viroporin, which has a similar structure to Vpu, therefore, the TM domain of Vpu could possibly be used as a target for novel antiviral drugs [87] .
INHIBITORS Entry Inhibitors
Infection of target cells by HIV is a complex, multi-stage process involving attachment to host cells and CD4 binding, coreceptor binding, and membrane fusion. Drugs that block HIV entry are collectively known as entry inhibitors, but comprise a complex group of drugs with multiple mechanisms of action depending on the stage of the entry process at which they act. All of these stages are mediated by the viral envelope (Env) proteins, gp120 and gp41, which are the only viral proteins that project from the membrane of the virion. Generally, the group of entry inhibitors can be subdivided into classes of agents that act at different stages of entry: attachment and CD4 binding, coreceptor binding, and fusion. Currently, only antagonists that block CCR5 binding (maraviroc) and fusion (enfuvirtide) have been approved by the FDA for treatment of HIV-infected patients, although strategies to inhibit other aspects of HIV entry are under development.
Drugs Blocking the gp120-CD4 Interaction
Small-molecule inhibitors of the CD4-gp120 binding interaction are NBD-556, NBD-557, BMS-378806 and BMS-488043 compounds (Fig. (5) ). The precise mechanism of action of these molecules is unclear yet but some studies have suggested that these compounds compete with CD4 for binding to gp120 while others indicate that they prevent conformational changes in gp120 upon CD4 engagement. BMS-806 has been discontinued in phase II clinical trial since amino acids, Trp 112, Thr 257, Ser 375, Phe 382, Met 426, and 'phenylalanine 43 cavity' on gp120 confer resistance to BMS-806.
Drugs Blocking the gp120-Coreceptor Interaction
CCR5 and CXCR4 are the critical coreceptors for HIV entry. A number of naturally occurring ligands block HIV infection by blocking Env binding to CCR5 but they have potentially undesirable agonist activity on CCR5. Therefore, several RANTES derivatives, including AOP-RANTES, NNY-RANTES, and PSC-RANTES, (Fig. (5) ) have been developed in an effort to maintain anti-HIV activity while reducing or eliminating the agonistic effects on CCR5. These agents compete with gp120 for binding to coreceptor and therefore are competitive antagonists of HIV infection. Another strategy developed was to design small molecules that can potentially bind to a hydrophobic pocket in the transmembrane helices of CCR5 and alter the conformation of the extracellular loops of HIV during coreceptor binding. The designed molecules aplaviroc (GW873140) and ancriviroc (SCH-C) (Fig. (5) ) went up to clinical trials but were discontinued due to idiosyncratic hepatotoxicity & elongated QT cardiac interval respectively. Vicriviroc (SCH-417690), a second-generation molecule of ancriviroc (SCH-C), is currently in phase III clinical trials. Maraviroc (UK-427857) got FDA approval in 2007 for the treatment of HIVinfected patients and is effective against CCR5-using (R5-tropic) HIV strains in the low nanomolar range. It is administered twice daily by oral route but dose depends on the presence or absence of CYP3A inducers or inhibitors in the antiviral regimen [88] .
Fusion Inhibitors
Pharmacological agents that disrupt gp41-mediated membrane fusion, collectively called fusion inhibitors, were the first entry inhibitors to be approved for the treatment of HIV infection. Synthetic peptides corresponding to the HR1 and HR2 domains of gp41 were found to have potent antiviral effects. The fusion inhibitor enfuvirtide (T-20) was approved by the FDA for the treatment of HIV-infected patients in 2003. Enfuvirtide is a linear, 36 amino acid synthetic peptide with a sequence identical to part of the HR2 region of gp41 and competes for binding to HR1. A number of other next-generation peptidic fusion inhibitors are under investigation, several of which have improved pharmacodynamics and efficacy compared with enfuvirtide. Additionally, certain agents are active against some enfuvirtide-resistant strains of HIV, and fusion inhibitors that bind to different functional domains of gp41 can have synergistic effects. However, since peptidic fusion inhibitors are not orally bioavailable and must be administered via injection, the development of small-molecule inhibitors of gp41 mediated fusion remains a goal in drug development [89] .
Nucleoside Reverse Transcriptase Inhibitors
The first ever reported anti-retroviral drug candidate zidovudine (AZT, Retrovir) is a thymidine analog, which was first synthesised in 1964 [90] but the synthetic procedure for zidovudine was further improved so as to use the D-mannitol as the starting material in place of the expensive thymidine (Scheme 1) [91] . Zidovudine was successfully evaluated as an antiviral agent in 1980 but its activity as a potential inhibitor of a viral enzyme, RNA dependent DNA polymerase (reverse transcriptase), was established in 1985 [92] . Zidovudine first gets phosphorylated into 5'-monophosphate and finally to the 5'-triphosphate by the cellular kinase enzymes to form zidovudine-5'-triphosphate (AZT-TP) which gets incorporated on to the growing complementary DNA chain of the virion. This incorporation blocks the DNA polymerisation reaction and disrupts the proviral DNA synthesis leading to the termination of the viral life cycle (Fig. (6) ) [93, 94] . The loss in the activity is generally corresponded to the number of mutations taken place in the active site. Fig. (7) shows the chimera view of the active site of RT of a crystal structure (PDB id 3KLE) interacting with zidovudine terminating the DNA synthesis. The active site shows the interaction of AZT with the complementary base on the DNA strand. It also inhibits cellular -DNA polymerase but at a hundred fold higher concentration as compared to the concentration required to inhibit reverse transcriptase. Abacavir (ABC), Didanonise (ddI), Emtricitabine (FTC), Stavudine (d4T), Lamivudine (3TC), Tenofovir disoproxil fumarate (TDF), Zalcitabine (ddC) are other drugs in this class ( Table 2) which work on the similar mechanism to inhibit the viral replication. Out of these drugs, three anti-HIV drugs, i.e. lamivudine, zalcitabine, and emtricitabine, are based on cytidine derivatives. The synthesis of lamivudine (Scheme 2) was first reported in 1992 in a racemic form where in levorotatory (-) enantiomer was found to be less toxic as compared to the dextrorotatory (+) enantiomer [95] . The 5-fluoro derivative of lamivudine (emtricitabine) was synthesised in 1992 [96] . Further, Didanosine, Abacavir and Tenofovir were reported as guanosine-based inhibitors with significant anti-HIV activity [97] .
Although these drugs were well evaluated with respect to their pharmacokinetics (ADMET) but due to the emergence of viral resistance and toxicity in monotherapy of HIV, combination chemotherapy was evaluated using zidovudine and zalcitabin which proved to be well tolerated and showed significant potential to reduce the viral load after alternative 7-days regimen. NRTIs were invariable tested for combination therapy and the results showed that the combination of lamivudine with zidovudine was found to be significantly efficacious as compared to the monotherapy of zidovudine [98] . 
Nonnucleoside Reverse Transcriptase Inhibitors
This class of inhibitor was first discovered in 1990 with the identification of the first tricyclic benzodiazepine molecule R14458 (Fig. (8a) ) from anti-HIV screening of 600 compounds otherwise inactive against various other biochemical targets. Then a series of similar compounds with improved anti-HIV activity were synthesized on the basis of structure activity relationship (SAR) studies leading to a molecule R82913 (Fig. (8a) ) with more potent activity [99] . Further, another group reported a series of diaryldiazepinones out of which, BI-RG-587 was identified as a potent NNRT inhibitor in cell culture and after many preclinical and clinical trials it managed to get the first ever NNRTI regulatory approval with a generic name nevirapine [100]. The synthetic route using 4-methyl-3-[(tertbutoxycarbonyl)amino]-2-methoxypyridin as an intermediate compound can be utilised for the synthesis of nevirapine (Scheme 3) [101] and efavirenz was reported to be enantioselectively synthesized by 4-chloroaniline as the starting material (Scheme 4) [102] .
Nevirapine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing the disruption of the catalytic site. Fig. (9) shows the pymol view of the x-ray crystal structure of Nevirapine bound to HIV-1 RT. It does not compete with nucleoside triphosphate. In cell culture, nevirapine demonstrated the synergistic effect against HIV in combination with NRTIs like AZT, ddI, d4T, 3TC and protease inhibitor saquinavir. Similarly, a large number of compounds were screened in a cell culture method for their anti-HIV-1RT activity from which aryl piperazine derivative; U-80493E (Fig. (8b) ) was selected as a lead molecule which was optimised to give a clinical candidate atevirdine. Unfortunately, atevirdine (Fig.  (8b) ) was not very active even at a dose of 600mg tid so further optimization was done on the indole and pyridine portion of the molecule to finally give delavirdine ( Table 2 ) [103, 104] . Likewise, L-608,788 (Fig. (8c) ) became the lead molecule in another class of dihydroquinazolinethione derivatives and optimisation on this molecule led to a very potent once daily dosing molecule Efavirenz [105] . Fig. 10 shows the pymol view of the x-ray crystal structure of efavirenz bound to HIV-1 RT.
Integrase Inhibitor
October 2007, FDA approved the first drug Raltegravir (MK-0518) in the integrase-inhibitor class for the effective treatment of HIV as a part of combination antiretroviral therapy. Raltegravir is a structural analogue of di-keto acid class of compounds and constitutes a -hydroxy-ketone structural motif. This structural motif possesses metalchelating functions which interact with divalent metals within the active site of HIV-1 integrase. The insertion of HIV-1 viral genomic DNA into the host chromosome is a process often referred to as strand transfer. Raltegravir and its related molecules inhibit this latter step, and as a result are often referred to as "strand-transfer inhibitors." Raltegravir has been shown to have a 50% inhibitory concentration (IC50) of approximately 10 nM [106] . Further, various quinolone acid derivatives have been developed as an integrase inhibitors [107] . 
Protease Inhibitors
Protease is one of the most important targets of HIV-1, which have been identified and utilised for the design and development of anti-HIV drugs. Various molecules have been co-crystallised with the enzyme protease and submitted to protein data bank. Fig. 11 shows the pymol view of the co-crystal structure and drug-amino acid interactions of indinavir at the active site of HIV protease enzyme. Mutagenic efficiency of HIV is very high which results in the generation of new highly resistant viral strains of HIV with multiple mutations in their proteases. Therefore, novel inhibitors with new mode of action at the enzyme are required. Recently, Shityakov et al. developed a library of diverse chemical compounds on the bases of Indinavir and screened them for plausible anti-protease activity. One unique compound with different protease binding ability was reported for which further studies may provide useful information towards the rational design of HIV-1 protease inhibitors [108] .
New Therapeutics (Carbohydrate-Binding Proteins)
Carbohydrate-binding proteins (CBP) show specific recognition for mannose (Man) and N-acetylglucosamine (GlcNAc) and are endowed with a remarkable anti-HIV activity in cell culture. CBP occur as monomer, dimer, trimer or tetramer peptides with a molecular weight of approx. 8.5 kDa upto 50 kDa. CBP may contain 2 to 12 carbohydratebinding sites per molecule, depending on the nature and its oligomerization state. CBP shows potential anti-HIV activity because they inhibit viral infection in the lower nano-or even subnanomolar range. The CBP's also prevent virus transmission from virus-infected cells to uninfected Tlymphocytes. They act by inhibiting the virus entry (i.e. fusion) into its target cell by direct binding to the glycans that are abundantly present on the HIV-1 gp120 envelope. They cross-link several glycans during virus/cell interaction and/or freeze the conformation of gp120 consequently preventing further interaction with the coreceptor. CBP's have a unique mechanism of antiviral action, drug resistance profile and an intrinsic capacity to trigger a specific immune response against HIV strains after glycan deletions. CBP from various sources have been reported [109] . Griffithsin (GRFT) is one such CBP with a novel anti-HIV protein consisting of 121-amino acid sequence isolated from an aqueous extract of the red alga Griffithsia sp. The pymol view of the crystal structure of griffithsin (Fig. (12) ) shows that it is a dimer with a unique structure. GRFT forms a complex with mannose at three almost identical carbohydrate binding sites on each monomer displaying a potent antiviral activity against HIV-1 with EC50 values ranging from 0.043 to 0.63 nM. At high concentration of 783 nM, GRFT was not lethal to the host cells. GRFT blocks gp120 binding to receptor-expressing cells and itself gets bind to the viral coat glycoproteins gp120, gp41, and gp160 in a glycosylationdependent manner. Antiviral potency of griffithsin is likely due to the presence of multiple, similar sugar binding sites that provide redundant attachment points for complex carbohydrate molecules present on viral envelopes [110] . Fig. (12) . Pymol based representation of the two fold symmetry of crystal structure (PDB id 2GUD) of Griffithsin shown as a yellow broken line. Chain A is represented in blue and Chain B in red. Each monomer is bound to three molecules of mannose.
FUTURE STRATEGIES & CONCLUSION
The following section concludes some of the challenges to be encountered during the design and development of new classes of antiretroviral inhibitors acting on some of the discussed targets. Recent, Shityakov and group has opened a new avenue in the HIV research claiming that protein 'transportin-SR2' is the actual nuclear import protein for HIV-1 integrase rather than transportin-SR1 [111] . Since very limited information is available about the novel targets therefore further improvement in the existing inhibitors against established targets using QSAR techniques is comparatively less challenging than the de novo design of antiretroviral drugs against novel therapeutic targets (112). Although various drug design and discovery technologies have been introduced over the past few years, the result remains unpredictable in finding effective inhibitors for these novel targets. Nevertheless new therapeutic approaches like carbohydrate binding proteins from various sources including marine has shown the promising results. Therefore the focus of the antiretroviral research should be on such therapeutics. Further, these proteins should be taken to the clinical trials and should also be tried in combinations with other antiretroviral drugs as a multi drug therapy for the treatment of HIV/AIDS. The goal of this review was to provide the essential steps in the HIV replication cycle, to cover all potential HIV targets and their available inhibitors in view of a medicinal chemist. After an exhaustive exploration of therapeutic targets and inhibitors against HIV we need to further expand the existing weapon store of antiretroviral drugs by focusing on novel targets, novel therapeutics from various sources including marine and interdisciplinary collaborative effort.
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